March 20, 2017 / 11:28 AM / 9 months ago

BRIEF-Aevi Genomic Medicine provides top-line results from saga trial

March 20 (Reuters) - Aevi Genomic Medicine Inc:

* Aevi Genomic Medicine provides top-line results from the saga trial of aevi-001

* Aevi Genomic Medicine Inc - trial did not meet primary endpoint

* Aevi Genomic Medicine Inc - trial was well tolerated with no serious adverse events

* Aevi Genomic Medicine Inc - safety analysis demonstrated that aevi-001 was well tolerated at all doses

* Aevi Genomic Medicine- moving forward plan to explore higher doses, refined genomic biomarker,study pediatric patients which should enhance response rates,effect size of aevi-001 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below